These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35616365)

  • 21. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V; Lin H; Velazquez J; Batajoo A; Parekh D; Stanton W; Abhyankar H; El-Mallawany NK; Agrusa J; Eckstein O; Gulati N; Schwartz J; Woods-Swafford W; Boyd J; Saha A; Allen CE; McClain KL
    Br J Haematol; 2024 May; 204(5):1882-1887. PubMed ID: 38501390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
    Aricò M
    Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
    Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
    Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.
    Heisig A; Sörensen J; Zimmermann SY; Schöning S; Schwabe D; Kvasnicka HM; Schwentner R; Hutter C; Lehrnbecher T
    Oncotarget; 2018 Apr; 9(31):22236-22240. PubMed ID: 29774135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
    Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
    Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
    Abla O
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
    Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Allen CE
    Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
    Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
    Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib.
    Konstantinou MP; Lucas P; Uthurriague C; Severino-Freire M; Spenatto N; Gaudin C; Lamant L; Tournier E; Bulai-Livideanu C; Meyer N; Paul C
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e120-e121. PubMed ID: 32757402
    [No Abstract]   [Full Text] [Related]  

  • 40. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.